Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML),
can be associated to cardiovascular (CV) adverse events (AEs). A case/non-case study …

… . Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic
myeloid leukemia: a population-based cohort study. Ann Intern Med 2016;165:161–6.doi:10.7326/…

… The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved
the prognosis of patients with chronic myeloid leukemia (CML). Although there are some …

… cardiovascular disease, diabetes, and kidney disease and for patient characteristics, including
race and age. Moreover, early signs of arterial hypertension during TKI treatment should …

… of vascular disease. We herein provide the example of tyrosine kinase inhibitors utilized in
chronic myelogenous leukemia to … the vascular considerations for the clinical care of chronic …

… the treatment of chronic myelogenous leukemia, with many … , clinical experience with tyrosine
kinase inhibitors (particularly … on various organs, particularly the cardiovascular system. …

… nearly equally distributed among cardiovascular, cerebrovascular, and peripheral vascular.
Venous thrombotic events were reported in 6% of patients with chronic phase (CP) disease …

… Vasospastic and vaso-occlusive vascular events, such as ischemic heart disease, ischemic
cerebrovascular events, and occlusive peripheral artery disease have been correlated with …

… of chronic myeloid leukemia (CML), and it has been investigated as a druggable target of
tyrosine kinase inhibitors (… accidents, coronary artery disease, or peripheral arterio-occlusive …

… some other kinases … vascular permeability. Therefore, theoretically imatinib may have a
role in attenuating inflammation and restoring vascular integrity in inflammatory vascular leak …